You are here:Home-Chemical Inhibitors & Agonists-Ras-Raf-MAPK-ERK Pathway-Ras-BBO-8520
BBO-8520

Chemical Structure : BBO-8520

CAS No.: 2892613-01-1

BBO-8520 (BBO8529, BBO 8520)

Catalog No.: PC-22123Not For Human Use, Lab Use Only.

BBO-8520 is a potent, selective and covalent inhibitor of KRAS G12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding.

Packing Price Stock Quantity
25 mg Get quote
50 mg Get quote
100 mg Get quote
250 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC)

Biological Activity

BBO-8520 is a potent, selective and covalent inhibitor of KRAS G12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding.
BBO-8520 binds in the switch II pocket and covalently modifies both the (ON) and (OFF) forms of KRASG12C independently of any other partner proteins.
BBO-8520 inhibits KRASG12C (ON) by locking the GTP-bound protein in state 1.
BBO-8520 displays highly significant binding to KRAS G12C in a global cysteine proteome analysis and is 100x more selective for KRASG12C than for WT KRAS and other mutant isoforms, with no measurable activity against N- or H-RAS.
BBO-8520 has sub-nanomolar potency against KRASG12C mutant cell lines.
BBO-8520 rapidly and completely blocks the RAS-RAF1 interaction in effector binding assays, at least 30x more potent than sotorasib and adagrasib at preventing outgrowt in long-term clonogenic assays.
BBO-8520 (10 mg/kg, daily dosing, oral) causes significant tumor volume regression in the KrasG12C-p53 driven GEMM model, exhibits in vivo target engagement and pERK inhibition in the MIAPaCa-2 and H358 KRASG12C mutant tumor models.

Physicochemical Properties

M.Wt 729.75
Formula C35H33F6N7O2S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

4-(4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6-(trifluoromethyl)quinazolin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

References

1. Anna E. Maciag, et al. Cancer Res (2024) 84 (7_Supplement): ND07.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: